Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523374-17-01

Acronym

PI24/01356

Enrollment

Registered

2025-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Brief summary

Myocardium insulin resistance

Detailed description

Coronary flow, Heart function

Interventions

DRUGOzempic 1 mg solution for injection in pre-filled pen

DRUGDapagliflozin 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Myocardium insulin resistance	—

Secondary

Measure	Time frame
Coronary flow, Heart function	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026